Molecular testing for FLT3 mutations aids in accurate risk assessment and treatment guidance, with ongoing research focusing on overcoming treatment resistance and enhancing outcomes for FLT3-mutated AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.